Atherosclerotic Cardiovascular Disease in Cardiovascular–Kidney-Metabolic Syndrome

Atherosclerotic cardiovascular disease (CVD) remains an important cause of morbidity and mortality globally. The novel American Heart Association cardiovascular kidney metabolic health framework highlights a graded accumulation of these risk enhancers that culminates in myocardial infarction, stroke, and peripheral arterial disease. The framework is supplemented by risk prediction models that allow earlier detection in order to implement risk reduction measures. The current therapeutic landscape includes agents that are targeted to the kidney and metabolic enhancers with specific benefits of reduced cardiovascular events including atherosclerotic CVD.